Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Normanno N"'
Autor:
Cardone C., Blauensteiner B., Moreno-Viedma V., Martini G., Simeon V., Vitiello P. P., Ciardiello D., Belli V., Matrone N., Troiani T., Morgillo F., Zito Marino F., Dentice M., Nappi A., Boccaccino A., Antoniotti C., Cremolini C., Pietrantonio F., Prager G. W., Normanno N., Maiello E., Argiles G., Elez E., Signoriello G., Franco R., Falcone A., Tabernero J., Sibilia M., Ciardiello F., Martinelli E., ZITO MARINO, Federica
Background RAS mutations are the only validated biomarkers in metastatic colorectal cancer (mCRC) for anti-epidermal growth factor receptor (EGFR) therapy. Limited clinical information is available on AXL expression, marker of epithelial to mesenchym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4937b3b9337afc85a90006c6268b2a74
https://hdl.handle.net/11588/920571
https://hdl.handle.net/11588/920571
Autor:
PACILIO C, MORABITO A, NUZZO F, GRAVINA A, LABONIA V, LANDI G, ROSSI E, MAIO E, DI MAIO M, D'AIUTO G, BOTTI G, NORMANNO N, CHIODINI, Paolo, GALLO, Ciro, PERRONE, F, DE MATTEIS A, NCI NAPLES BREAST CANCER GROUP
Publikováno v:
British Journal of Cancer
The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 1
Autor:
FRANCO, Renato, Rocco G, Marino FZ, Pirozzi G, Normanno N, Morabito A, SPERLONGANO, Pasquale, STIUSO, Paola, Luce A, Botti G, CARAGLIA, Michele, ZITO MARINO, Federica
"Anaplastic lymphoma kinase (ALK) rearrangements (ALK-Rs) have been identified in 3-7% of all non-small-cell lung cancers (NSCLCs) and represent an important molecular target for NSCLC treatment. The authors discuss the role of ALK-Rs in the predicti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d4c08d971564f60ca55241fee6c032
http://hdl.handle.net/11591/232502
http://hdl.handle.net/11591/232502
Autor:
I. Vergote, A. González-Martín, I. Ray-Coquard, P. Harter, N. Colombo, P. Pujol, D. Lorusso, M.R. Mirza, B. Brasiuniene, R. Madry, J.D. Brenton, M.G.E.M. Ausems, R. Büttner, D. Lambrechts, M. Ausems, J. Brenton, M. Abreu, S. Balboni, S. Banerjee, M. Barberis, M.P. Barretina Ginesta, J.-F. Baurain, M. Bignami, L. Bjorge, P. Blecharz, I. Bruchim, M. Capilna, N. Cerana, A. Cicchetti, D. Collins, N. Concin, M. D’Incalci, B. Davidson, T. de la Motte Rouge, P. De Iaco, F. Demirkiran, H. Denys, T. Doerk, A. Dorum, A. Ferrero, A.P. Fidalgo, M. Genuardi, L. Gladieff, R. Glasspool, C. Grimm, M. Gultekin, E. Hahnen, A. Hasenburg, A. Hegmane, V. Heinzelmann, E. Hogdall, R. Janavicius, S. Jarmalaite, R. Kalachand, R. Kaneva, S. Kilickap, R. Kocian, D. Kolencik, R. Kristeleit, A. Kryzhanivska, A. Leary, B. Lemley, M. Ligtenberg, J.A. López-Guerrero, C.J. Lord, E. Avall-Lundqvist, J. Maenpaa, S. Mahner, F. Marmé, C. Marth, I. McNeish, S. Merkelbach-Bruse, M. Mourits, N. Normanno, A. Oaknin, K. Ojamaa, C. Papdimitriou, F. Penault-Llorca, A.M. Perrone, S. Pignata, E. Pikarsky, E. Rouleau, M. Rubio, A. Sapino, B. Schmalfeldt, J. Sehouli, R. Shapira, K.D. Steffensen, V. Sukhin, J. Syrios, Z. Szallasi, C. Taskiran, M. Terzic, M. Tischkowitz, I. Toth, K. Van de Vijver, M.A. Vardar, B. Wasag, P. Wimberger, E. Witteveen
Publikováno v:
Annals of Oncology, 33, 3, pp. 276-87
Vergote, I, González-Martín, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M R, Brasiuniene, B, Madry, R, Brenton, J D, Ausems, M G E M, Büttner, R, Lambrechts, D, European experts’ consensus group & Dahl Steffensen, K 2022, ' European experts consensus : BRCA/homologous recombination deficiency testing in first-line ovarian cancer ', Annals of Oncology, vol. 33, no. 3, pp. 276-287 . https://doi.org/10.1016/j.annonc.2021.11.013
ANNALS OF ONCOLOGY
Annals of Oncology, 33, 276-87
Vergote, I, González-Martín, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M R, Brasiuniene, B, Madry, R, Brenton, J D, Ausems, M G E M, Büttner, R, Lambrechts, D, European experts’ consensus group & Dahl Steffensen, K 2022, ' European experts consensus : BRCA/homologous recombination deficiency testing in first-line ovarian cancer ', Annals of Oncology, vol. 33, no. 3, pp. 276-287 . https://doi.org/10.1016/j.annonc.2021.11.013
ANNALS OF ONCOLOGY
Annals of Oncology, 33, 276-87
BACKGROUND: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typicall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048b3ea84583ffb10df0f113446b4777
Autor:
Nicla La Verde, Fiamma Buttitta, Maria Angela Bella, Massimo Barberis, Ettore Capoluongo, Chiara Trevisiol, Pierosandro Tagliaferri, Enrico Ricevuto, Nicola Normanno, Nicoletta Colombo, Matilde Pensabene, Antonio Russo, Sandro Pignata, Anna Sapino, Domenica Lorusso, Liliana Varesco, Maurizio Genuardi, Lorena Incorvaia, Massimo Gion, Valentina Guarneri, Laura Cortesi, Pierfrancesco Tassone, Paolo Radice, Mauro Truini, Paolo Marchetti, Stefania Gori, Antonio Marchetti, Barbara Pasini, Paola Carrera
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942108ee20348ca4ec8b28d92ca4333a
http://hdl.handle.net/10447/437173
http://hdl.handle.net/10447/437173
Autor:
Ettore Capoluongo, Sandro Pignata, Paola Carrera, Enrico Ricevuto, Maurizio Genuardi, Paolo Radice, Antonio Russo, Nicoletta Colombo, Carmine Pinto, Stefania Gori, Barbara Pasini, Paolo Marchetti, Nicola Normanno, Valentina Guarneri, Laura Cortesi, Antonio Marchetti, Mauro Truini, Maria Angela Bella, Pierosandro Tagliaferri, Pierfrancesco Tassone, Gaetano De Rosa, Francesca Fenizia, Claudio Clemente, Liliana Varesco
In the last 20 years, following the identification of the BRCA1 and BRCA2 genes (hereinafter referred to as the BRCA genes), preventive pathways have been developed for the identification and clinical management of individuals at high risk of develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb9b4ad22ad35cde975131fad7a5a30
http://hdl.handle.net/11577/3362422
http://hdl.handle.net/11577/3362422
Autor:
Nicola Normanno, Anna Maria Rachiglio, Giuseppe Antinolfi, Pietro Carotenuto, Renato Franco, Alfonso Illiano, Francovito Piantedosi, Alessandro Morabito, Gerardo Botti, Antonella De Luca, Cristin Roma, Raffaella Pasquale
Publikováno v:
Pharmacogenomics and personalized medicine
The epidermal growth factor receptor (EGFR) is expressed in the majority of non- small-cell lung cancer (NSCLC). However, only a restricted subgroup of NSCLC patients respond to treatment with the EGFR tyrosine kinase inhibitor (EGFR TKI) gefitinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aae62c090c8a3bfdfb573e7eb9bf1d1b
http://hdl.handle.net/11591/328837
http://hdl.handle.net/11591/328837
Autor:
Guglielmo Nasti, Chiara Carlomagno, Carmela Romano, Francesco Perrone, Sabino De Placido, Tizana Pia Latiano, Maria Carmela Piccirillo, Domenico Bilancia, Pasqualina Giordano, Lucrezia Silvestro, Oscar Alabiso, Antonio Avallone, Nicola Normanno, Anna Nappi, Alessandro Ottaiano, Alfonso De Stefano, Gerardo Rosati, Evaristo Maiello, Bruno Daniele, Antonino Cassata, Rosario Vincenzo Iaffaioli
Publikováno v:
Clinical Colorectal Cancer. 19:270-276
Purpose: To assess whether panitumumab is active in patients with cetuximab-refractory metastatic colorectal cancer (mCRC). Patients and Methods: Eligible patients had pretreated RAS (renin–angiotensin system) wild-type mCRC that progressed after c
Autor:
Erika Martinelli, Teresa Troiani, Lucia Esposito, Nicola Normanno, Davide Ciardiello, Carmine Pinto, Evaristo Maiello, Chiara Cremolini, Tiziana Latiano, Vincenzo Famiglietti, Giuseppe Santabarbara, Giulia Martini, Antonio Avallone, Stefania Napolitano, Fortunato Ciardiello, Filippo Pietrantonio
Publikováno v:
Cancers
Volume 13
Issue 22
Cancers, Vol 13, Iss 5715, p 5715 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5715, p 5715 (2021)
The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy
Autor:
Francesco Izzo, Anna Maria Trotta, Vittorio Albino, Lucrezia Silvestro, Antonio Avallone, Raffaele Palaia, Gerardo Botti, Monica Capozzi, Paolo Chiodini, Rossana Casaretti, Carmine Picone, Stefania Scala, Nicola Normanno, Mario Tamburini, Andrea Belli, Crescenzo D'Alterio, Anna Maria Rachiglio, Massimiliano Di Marzo, Guglielmo Nasti, Paolo Delrio, Cristin Roma, Anna Nappi, Carmela Romano, Antonella Petrillo, Antonino Cassata, Gianfranco De Feo, Alessandro Ottaiano, Salvatore Tafuto, Maria Napolitano, Alfonso Amore, Alfonso De Stefano, Ugo Pace, Luigi Portella
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
BMC Cancer
Background Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC). However, patients